| Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation JN Kochenderfer, ME Dudley, RO Carpenter, SH Kassim, JJ Rose, ... Blood 122 (25), 4129-4139, 2013 | 702 | 2013 |
| Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells P Kebriaei, H Singh, MH Huls, MJ Figliola, R Bassett, S Olivares, B Jena, ... The Journal of clinical investigation 126 (9), 3363, 2016 | 534 | 2016 |
| Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor B Jena, G Dotti, LJN Cooper Blood 116 (7), 1035-1044, 2010 | 499 | 2010 |
| Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells H Singh, MJ Figliola, MJ Dawson, S Olivares, L Zhang, G Yang, S Maiti, ... PLoS One 8 (5), e64138, 2013 | 216 | 2013 |
| CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo G Tian, AN Courtney, B Jena, A Heczey, D Liu, E Marinova, L Guo, X Xu, ... The Journal of clinical investigation 126 (6), 2341, 2016 | 153 | 2016 |
| Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials B Jena, S Maiti, H Huls, H Singh, DA Lee, RE Champlin, LJN Cooper PLOS ONE 8 (3), e57838, 2013 | 142 | 2013 |
| Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies P Kebriaei, H Huls, B Jena, M Munsell, R Jackson, DA Lee, PB Hackett, ... Human gene therapy 23 (5), 444-450, 2011 | 138 | 2011 |
| Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity D Rushworth, B Jena, S Olivares, S Maiti, N Briggs, S Somanchi, J Dai, ... Journal of immunotherapy (Hagerstown, Md.: 1997) 37 (4), 204, 2014 | 37 | 2014 |
| Driving CAR-Based T-Cell Therapy to Success B Jena, JS Moyes, H Huls, LJN Cooper Current hematologic malignancy reports 9 (1), 50-56, 2014 | 36 | 2014 |
| Anti-CD19 scFv (FMC63) polypeptide LJN Cooper, J Bipulendu, S Maiti US Patent 9,701,758, 2017 | 30 | 2017 |
| Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor P Kebriaei, H Huls, H Singh, S Olivares, M Figliola, S Maiti, S Shihuang, ... Blood 124 (21), 311-311, 2014 | 29 | 2014 |
| CARs in Chronic Lymphocytic Leukemia–Ready to Drive C Hosing, P Kebriaei, W Wierda, B Jena, LJN Cooper, E Shpall Current hematologic malignancy reports 8 (1), 60-70, 2013 | 25 | 2013 |
| Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ … P Kebriaei, SO Ciurea, MH Huls, H Singh, S Olivares, S Su, MJ Figliola, ... Blood 126 (23), 862-862, 2015 | 19 | 2015 |
| CARs: driving T-cell specificity to enhance anti-tumor immunity P Kebriaei, SS Kelly, P Manuri, B Jena, R Jackson, E Shpall, R Champlin, ... Frontiers in bioscience (Scholar edition) 4, 520, 2012 | 18 | 2012 |
| First clinical trials employing Sleeping Beauty gene transfer system and artificial antigen presenting cells to generate and infuse T cells expressing CD19-specific chimeric … H Huls, H Singh, S Olivares, M Figliola, PR Kumar, B Jena, MA Forget, ... Blood 122 (21), 166-166, 2013 | 17 | 2013 |
| Good T cells for bad B cells LJN Cooper, B Jena, CM Bollard Blood 119 (12), 2700-2702, 2012 | 17 | 2012 |
| Donor-derived anti-CD19 chimeric-antigen-receptor-expressing T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation ME Dudley, RO Carpenter, SH Kassim, JJ Rose, W Telford, FT Hakim, ... Blood 122 (21), 151-151, 2013 | 16 | 2013 |
| Chimeric antigen receptor-targeting monoclonal antibodies LJ Cooper, J Bipulendu, H Singh, D Rushworth US Patent App. 14/893,223, 2014 | 15 | 2014 |
| CHIMERIC ANTIGEN RECEPTORS (CAR) TO SELECTIVELY TARGET PROTEIN COMPLEXES LJN Cooper, B Jena US Patent 20,170,334,968, 2017 | 12 | 2017 |
| GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS LJN Cooper, H Singh, H Huls, S Olivares, B Jena, K Patel US Patent 20,170,333,480, 2017 | 8 | 2017 |
